Mesothelioma
📧 Sign up to get email alerts when something new happens for Mesothelioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma [Phase 1, Phase 2]
Phase 1/2 trial evaluating pevonedistat alone and with chemotherapy in mesothelioma has been terminated, with results posted in May 2024.
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer [Phase 1, Phase 2]
A two-part Phase 1/2 trial of BIW-8962 as monotherapy in lung cancer has been terminated; the study evaluated Non-Small Cell Lung Cancer, Sm…
-
CLINICAL_TRIALS trial_result · 2024-02-29Clinical Trial Update: Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma [Phase 2]
Phase 2 trial update evaluating nivolumab and ipilimumab with or without UV1 vaccination as second-line therapy for malignant mesothelioma.
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: DENdritic Cell Immunotherapy for Mesothelioma [Phase 2, Phase 3]
A Phase 2/3 clinical trial update for DENdritic Cell immunotherapy in mesothelioma has completed.
-
CLINICAL_TRIALS trial_result · 2024-01-26Clinical Trial Update: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma [Phase 1, Phase 2]
A clinical trial update for RSO-021 in malignant pleural effusion due to advanced/metastatic solid tumors including mesothelioma across Phas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) [Phase 2]
Phase 2 trial evaluating niraparib in BAP1- and DDR-deficient neoplasms including mesothelioma and uveal melanoma has completed with results…
-
CLINICAL_TRIALS trial_result · 2023-08-24Clinical Trial Update: Folinic Acid for Prevention of Pemetrexed-induced Toxicity [Phase 4]
Phase 4 trial update evaluating folinic acid to prevent pemetrexed-induced toxicity in NSCLC, mesothelioma, and thymoma.
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity [Phase 1, Phase 2]
Clinical trial exploring risk factors of immune checkpoint inhibitor–mediated liver, GI, endocrine, and skin toxicity across early-phase tri…
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC [Phase 2]
Phase 2 trial update for UNITO-001 in HRR/PD-L1 positive malignant pleural mesothelioma and non-small cell lung cancer.
-
EMA approval · 2023-01-19EMA Authorised: Pemetrexed Baxter (pemetrexed disodium heptahydrate) — Baxter Holding B.V.
The EMA authorised Pemetrexed Baxter (pemetrexed disodium heptahydrate) for non-small cell lung carcinoma and mesothelioma.
-
CLINICAL_TRIALS trial_result · 2022-05-13Clinical Trial Update: Dose Individualization of Pemetrexed - IMPROVE-II [Phase 4]
Phase 4 trial update on dose individualization of pemetrexed (IMPROVE-II) has been terminated.
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Dose Individualization of Pemetrexed - IMPROVE-III [Phase 4]
Phase 4 trial update on dose individualization of pemetrexed (IMPROVE-III) completed.
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases [Phase 1, Phase 2]
Phase 1/2 trial evaluating continuous 24-hour IV mithramycin for thoracic malignancies with pleuropulmonary metastases was terminated; resul…
-
EMA withdrawal · 2021-11-26EMA Withdrawn: Pemetrexed Lilly (pemetrexed) — Eli Lilly Netherlands
Pemetrexed Lilly (pemetrexed) was withdrawn from EMA evaluation across indications for non-small cell lung cancer and mesothelioma.
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors [Phase 1]
Phase 1 study results for INCB001158, an arginase inhibitor, as a single agent and in combination with immune checkpoint therapy, in patient…
-
EMA withdrawal · 2021-07-29EMA Withdrawn: Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited) (pemetrexed ditromethamine) — Pfizer Europe MA EEIG
The EMA status indicates the pemetrexed product previously marketed by Hospira/Pfizer has been withdrawn. It was indicated for non-small cel…
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma [Phase 2]
Phase II trial update for MEDI4736 (durvalumab) in combination with chemotherapy as first-line treatment for unresectable mesothelioma; stud…
-
CLINICAL_TRIALS trial_result · 2020-07-17Clinical Trial Update: Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) [Phase 2]
Phase II trial update for Anetumab Ravtansine as second-line treatment in malignant pleural mesothelioma has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2019-12-30Clinical Trial Update: Mithramycin for Lung, Esophagus, and Other Chest Cancers [Phase 2]
Phase 2 trial of Mithramycin for lung, esophageal, and other chest cancers was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial update for autologous CAR-T/TCR-T cell immunotherapy targeting multiple malignancies; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer [Phase 1, Phase 2]
Phase 1/2 trial of CAR T cell therapy targeting mesothelin in metastatic cancer shows terminated status with posted results.
-
CLINICAL_TRIALS trial_result · 2019-06-06Clinical Trial Update: SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma [Phase 1, Phase 2]
Phase 1/2 trial evaluating SS1P with pentostatin and cyclophosphamide for mesothelioma and related cancers has completed with results posted…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy [Phase 2]
Phase 2 clinical trial update for intraperitoneal hyperthermic chemotherapy in several gynecologic and related cancers; current status not s…
-
CLINICAL_TRIALS trial_result · 2019-03-18Clinical Trial Update: Nintedanib (BIBF 1120) in Mesothelioma [Phase 2, Phase 3]
Clinical trial updates for nintedanib in mesothelioma (Phase 2/3) with terminated status and posted results.
-
CLINICAL_TRIALS research · 2019-02-22Clinical Trial Update: Chest Wall Motion Analysis in Disease
This completed clinical trial examines chest wall motion analysis across several diseases, including mesothelioma, lung cancer, COPD, cystic…